All In Biotech

Drug Trial Radar · NCT05211830

A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Dec 7, 2021

Primary completion

Jun 10, 2025

Study completion Aug 20, 2025

Sponsor

Lead sponsor
Sixera PharmaIndustry
Sponsor type
Industry
First posted
Jan 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.

Conditions

  • Netherton Syndrome

Interventions

  • SXR1096 creamDrug

    Skin cream to be applied twice a day to a predefined area of the skin

  • Placebo creamDrug

    Skin cream to be applied twice a day to a predefined area of the skin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of the treatment with SXR1096 compared to placebo in initial cohort of adultsTime frame: 4 week
  2. Safety of the treatment with SXR1096 compared to placebo in adults and adolescentsTime frame: 4 weeks
  3. Efficacy of the treatment with SXR1096 compared to placebo in adults and adolescentsTime frame: 4 weeks

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical University Innsbruck, Tirol Kliniken

    Innsbruck, Austria

  • Saint Louis Hospital

    Paris, France

  • Necker Hospital

    Paris, France

  • University of Freiburg

    Freiburg im Breisgau, Germany

  • Karolinska Hospital, Huddinge

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.